NewslettersHuman Immunology News Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation By Danielle Corrigan - May 5, 2022 0 Gilead Sciences, Inc. and Dragonfly Therapeutics announced a collaboration designed to advance a number of Dragonfly’s novel NK cell engager-based immunotherapies for oncology and inflammation indications. [Gilead Sciences, Inc.] Press Release